- Home
- BFST vs AKBA Comparison
BFST vs AKBA Comparison
Compare BFST & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- AKBA
- Stock Information
- Founded
- BFST 2006
- AKBA 2007
- Country
- BFST United States
- AKBA United States
- Employees
- BFST N/A
- AKBA N/A
- Industry
- BFST Major Banks
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- AKBA Health Care
- Exchange
- BFST Nasdaq
- AKBA Nasdaq
- Market Cap
- BFST 719.4M
- AKBA 861.7M
- IPO Year
- BFST 2018
- AKBA 2014
- Fundamental
- Price
- BFST $23.92
- AKBA $2.93
- Analyst Decision
- BFST Strong Buy
- AKBA Strong Buy
- Analyst Count
- BFST 3
- AKBA 5
- Target Price
- BFST $30.00
- AKBA $6.90
- AVG Volume (30 Days)
- BFST 93.3K
- AKBA 2.9M
- Earning Date
- BFST 10-23-2025
- AKBA 11-06-2025
- Dividend Yield
- BFST 2.38%
- AKBA N/A
- EPS Growth
- BFST 3.92
- AKBA N/A
- EPS
- BFST 2.51
- AKBA N/A
- Revenue
- BFST $291,096,000.00
- AKBA $203,733,000.00
- Revenue This Year
- BFST $25.00
- AKBA $43.91
- Revenue Next Year
- BFST $17.32
- AKBA $32.09
- P/E Ratio
- BFST $9.37
- AKBA N/A
- Revenue Growth
- BFST 17.48
- AKBA 16.75
- 52 Week Low
- BFST $20.07
- AKBA $1.26
- 52 Week High
- BFST $30.30
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- BFST 46.93
- AKBA 50.85
- Support Level
- BFST $23.05
- AKBA $2.66
- Resistance Level
- BFST $24.32
- AKBA $3.01
- Average True Range (ATR)
- BFST 0.46
- AKBA 0.12
- MACD
- BFST -0.03
- AKBA 0.04
- Stochastic Oscillator
- BFST 50.78
- AKBA 75.71
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.